Panel Continues To Push For Obesity CV Guidance As It Backs Contrave Approval
• By Cathy Dombrowski
FDA signaled during an advisory committee on Orexigen's weight-loss drug Contrave that it could be ready to revise its obesity drug draft guidance, particularly with regard to cardiovascular goals, but stressed that for now, the drugs under review are to be judged by standards articulated in the draft document.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
